MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Halozyme Therapeutics Inc

Затворен

СекторЗдравеопазване

62.97 1.88

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

61.38

Максимум

63.06

Ключови измерители

By Trading Economics

Приходи

1K

137M

Продажби

7.9M

298M

P/E

Средно за сектора

18.604

63.778

EPS

1.26

Марж на печалбата

45.976

Служители

350

EBITDA

13M

203M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+7.11% upside

Дивиденти

By Dow Jones

Следващи печалби

6.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

690M

7.9B

Предишно отваряне

61.09

Предишно затваряне

62.97

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Halozyme Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.03.2025 г., 19:42 ч. UTC

Топ новини

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5.03.2025 г., 10:30 ч. UTC

Топ новини

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

1.11.2024 г., 11:30 ч. UTC

Топ новини

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Сравнение с други в отрасъла

Ценова промяна

Halozyme Therapeutics Inc Прогноза

Ценова цел

By TipRanks

7.11% нагоре

12-месечна прогноза

Среден 67.5 USD  7.11%

Висок 78 USD

Нисък 53 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Halozyme Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

8 ratings

5

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

62.85 / 63.8825Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.